WO2016181945A1 - 脳由来神経栄養因子の産生促進用組成物 - Google Patents
脳由来神経栄養因子の産生促進用組成物 Download PDFInfo
- Publication number
- WO2016181945A1 WO2016181945A1 PCT/JP2016/063797 JP2016063797W WO2016181945A1 WO 2016181945 A1 WO2016181945 A1 WO 2016181945A1 JP 2016063797 W JP2016063797 W JP 2016063797W WO 2016181945 A1 WO2016181945 A1 WO 2016181945A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bdnf
- production
- cocoa
- composition
- promoting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the present invention relates to a composition for promoting the production of brain-derived neurotrophic factor, and in particular, to a composition for promoting the production of brain-derived neurotrophic factor comprising cocoa polyphenol.
- BDNF protein Brain-derived neurotrophic factor
- TrkB receptor which is a receptor tyrosine kinase
- BDNF protein concentration in the serum decreases, but it has been reported that the decreased concentration is recovered by the success of an antidepressant (Non-patent Document 1). Therefore, it is expected that substances that act on this factor can improve the pathological conditions such as depression.
- An object of the present invention is to provide a novel composition for promoting BDNF production and a BDNF production promoter.
- an oil processing composition containing a high concentration of cocoa polyphenol is a BDNF protein concentration in human serum (particularly, a BDNF protein concentration in human serum having a low initial value of serum BDNF protein concentration).
- the present invention is based on this finding.
- a composition for promoting production of brain-derived nerve factor (BDNF) and a BDNF production promoter comprising cocoa polyphenol.
- BDNF brain-derived nerve factor
- a BDNF production promoter comprising cocoa polyphenol.
- the composition for promoting BDNF production and the BDNF production promoter according to [3] which are packaged for each effective intake for one day.
- [5] The composition for promoting BDNF production and the BDNF production promoter according to [3] or [4] above, wherein the daily intake effective for promoting BDNF production is 10 to 2000 mg (total amount of polyphenol).
- [6] The composition for promoting BDNF production and the BDNF production promoter according to any one of [1] to [5], wherein the cocoa polyphenol is ingested for 2 weeks or more.
- [6-1] The composition for promoting BDNF production according to any one of [1] to [6] above, wherein cocoa polyphenol is ingested at 10 to 2000 mg (total amount of polyphenol) per day for 2 weeks or more. And a BDNF production promoter.
- composition for promoting BDNF production and the BDNF production promoter according to any one of [1] to [6] and [6-1], which are in the form of an oil and fat processing composition.
- a method for promoting the production of BDNF comprising ingesting cocoa polyphenols for 2 weeks or more in a daily intake effective for promoting BDNF production.
- cocoa polyphenols for producing a composition for promoting production of BDNF or a BDNF production promoter.
- compositions for treating, preventing or ameliorating a disease and symptom for which BDNF production promotion is effective in treating, preventing or ameliorating the same, or a therapeutic, preventing or ameliorating agent for the disease and symptom Use of cocoa polyphenols.
- the agent and composition of the present invention include Even if it is taken for a long time, there are few side effects and it is advantageous in terms of high safety.
- cocoa polyphenol means a polyphenol contained in cocoa, that is, a cocoa-derived polyphenol. Therefore, typically, cocoa polyphenols extracted (including crude extraction) or purified (including crude purification) from cocoa plants or processed products thereof can be used as the active ingredient of the present invention. A part or all of the polyphenols prepared by the synthesis method may be used as cocoa polyphenols.
- examples of the cacao polyphenol include monomers such as catechin, epicatechin and clobamide, and oligomers (dimer or more) such as procyanidins and tannins obtained by polymerization of catechins and the like.
- cacao plants that can be used as raw materials for cacao polyphenols or processed products thereof include cacao bark, cacao leaves, cacao beans, cacao shells, cacao mass, defatted cacao mass, cocoa powder, etc.
- a processed product can be mentioned.
- the cocoa mass is obtained by grinding cocoa beans, and the defatted cocoa mass can be obtained by removing fats and oils from the cocoa mass.
- the method for removing oil and fat is not particularly limited, and can be performed according to a known method such as pressing. If defatted cocoa mass is crushed, it becomes cocoa powder.
- cacao mass or cocoa powder that has been subjected to atomization such as grinding or pulverization from the viewpoint of extraction efficiency.
- the cacao plant may include substances other than the cacao plant intentionally or unintentionally.
- a product other than the cacao plant can be included without intention or intention.
- the cocoa mass and cocoa powder can include substances other than cocoa plants intentionally or unintentionally.
- An extraction method using a cocoa plant or a processed product thereof as a raw material is known, and for example, a cocoa polyphenol-containing composition can be prepared according to the descriptions in JP2009-183229A and JP2011-93807A.
- the extraction solvent is not particularly limited, but water or alcohol such as ethanol is preferably used.
- a purification method using a cacao plant or a processed product thereof a known method such as a synthetic adsorbent, an ion exchange resin, ultrafiltration, or activated clay treatment can be used, and is particularly limited. is not.
- the cocoa polyphenol can contain 8% by mass or more, preferably 8 to 50% by mass, more preferably 8 to 30% by mass, based on the total mass of the cocoa polyphenol. More preferably, it can be contained in an amount of 8 to 20% by mass, still more preferably 8 to 15% by mass, particularly preferably 8 to 12% by mass, and most preferably 10 to 12% by mass.
- the polyphenol content can be measured by the Prussian blue method.
- commercially available epicatechin can be calculated as a standard substance according to the method described in Martin L. Price and Larry G. Butler, J. Agric Food Chem., Vol. 25, No. 6, 1268-1273, 1977. it can.
- a composition enriched with cocoa polyphenol in the present invention.
- a known method for example, described in JP-A-2009-183229
- the cocoa polyphenol concentrated composition obtained according to the above method can be used in the present invention.
- the composition for promoting BDNF production and the BDNF production promoter of the present invention may contain components derived from cocoa beans other than cocoa polyphenols. Good. Examples of such components include theobromine, caffeine, amino acids, peptides, fatty acids and the like. Moreover, the composition for BDNF production promotion of this invention and the BDNF production promoter may contain the component which does not originate in cocoa beans.
- the composition for promoting BDNF production and the BDNF production promoter of the present invention may contain N-phenylpropenoylamino acid amide at 100 mg / kg or less, preferably 80 mg / kg or less, more preferably 60 mg / kg or less. More preferably, the composition may be 50 mg / kg or less, and more preferably 25 mg / kg or less.
- N-phenylpropenoylamino acid amide is contained in cacao plants, but cocoa beans are treated according to the method described in Sanbongi et al., J. Agric Food Chem., Vol. 46, 454-457 (1998). By doing so, a cocoa polyphenol having the above-mentioned concentration can be obtained.
- the composition for promoting BDNF production and the BDNF production promoter of the present invention are preferably prepared without using a raw material containing isothiocyanate, more preferably a composition substantially free of isothiocyanate, can do.
- cacao polyphenol has a BDNF production promoting effect. Therefore, cocoa polyphenol can be used as a BDNF production promoter and can be used in a BDNF production promotion method. Cocoa polyphenol can also be used as a composition for promoting BDNF production.
- brain-derived neurotrophic factor (BDNF) production promotion means promoting the expression and secretion of BDNF in nerve cells, and the degree of promotion of BDNF production is indicated by the concentration of BDNF protein in serum. (See Example 1). Specifically, when the BDNF protein concentration in the serum after intake or administration of cocoa polyphenol exceeds the BDNF protein concentration in the serum before intake or administration, preferably about 1.1 times or more, More preferably about 1.2 times or more, even more preferably about 1.3 times or more, still more preferably 1.4 times or more, particularly preferably 1.5 times or more, and still more preferably 1.6 times or more. It can be determined that the production of BDNF has been promoted when the ratio is at least twice, more preferably at least 1.8 times, and most preferably at least twice.
- the BDNF production promotion method of the present invention can be carried out by ingesting or administering an effective amount of cocoa polyphenol to a human or non-human animal.
- cocoa polyphenols in the present invention may be used in humans and non-human animals and samples derived therefrom, and is intended for both therapeutic use and non-therapeutic use.
- non-therapeutic means not including an act of treating, treating or diagnosing a human (ie, a medical act on a human). Specifically, a doctor or a person who has received instructions from a doctor This means that it does not include methods for performing surgery, treatment or diagnosis on humans.
- cocoa polyphenols can be used for the treatment, prevention or improvement of diseases and symptoms for which BDNF production promotion is effective for the treatment, prevention or improvement.
- cocoa polyphenols can promote the production of BDNF, so far the expression and secretion levels of BDNF are psychological and neurological such as depression, depression, schizophrenia, developmental disorders, etc. It has been shown to affect disease (eg Chao, MV, Rajagopal, R., & Lee, FS (2006) Clin. Sci. (Lond.), 110, 167-173). Therefore, cocoa polyphenol can be used as a therapeutic, preventive or ameliorating agent for psychiatric / neurological diseases, and can also be used in a method for treating, preventing and improving psychiatric / neurological diseases.
- composition for promoting BDNF production and the BDNF production promoter of the present invention and the therapeutic agent, preventive agent and improving agent of the present invention can be provided in the form of pharmaceuticals, quasi-drugs, foods and drinks, feeds, etc. It can be carried out according to the description below.
- the BDNF production promotion method of this invention and the treatment method, prevention method, and improvement method of this invention can be implemented according to the following description.
- the cacao polyphenol which is an active ingredient of the present invention, can be orally administered to humans and non-human animals.
- Oral preparations include granules, powders, tablets (including sugar-coated tablets), pills, capsules, syrups, emulsions, and suspensions. These preparations can be formulated using a pharmaceutically acceptable carrier by a method usually performed in the art.
- Pharmaceutically acceptable carriers include excipients, binders, diluents, additives, fragrances, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc. Is mentioned.
- the cocoa polyphenol which is the active ingredient of the present invention, is a composition for promoting BDNF production according to the present invention, which can be administered to humans and non-human animals other than oral administration such as tube administration, nasal tube administration, infusion, suppository, etc. And depending on the shape of the BDNF production promoter.
- a viscous liquid composition containing cocoa polyphenols or a semi-solid composition containing cocoa polyphenols reduces the functions of chewing and swallowing, and can not be taken orally or orally. It can also be administered to human animals.
- composition for promoting BDNF production and the BDNF production promoter of the present invention are ingested or administered by other than oral ingestion, even if the functions of mastication and swallowing decrease due to aging, these humans and Treatment, prevention and improvement of non-human animal psychiatric / neurological diseases such as depression, depression, schizophrenia and developmental disorders can be expected.
- the cacao polyphenol which is an active ingredient of the present invention, can be taken orally by humans and non-human animals.
- cocoa polyphenol When cocoa polyphenol is orally ingested, the cocoa-derived polyphenol may be in an isolated, purified or crudely purified form, or may be in the form of a food containing cocoa polyphenol or a raw material for food.
- cocoa polyphenol can be arbitrarily selected from a normal temperature state, a warm state, a cold state, and the like when orally ingested by humans and non-human animals.
- the cocoa polyphenol which is an active ingredient of the present invention can be directly contained in the food, and the food is a food containing an effective amount of the cocoa polyphenol.
- “containing an effective amount” of cocoa polyphenol refers to a content such that cocoa polyphenol is ingested within the range described below when an amount normally consumed in each food is ingested.
- Food means health food, functional food, health functional food (for example, food for specified health use, functional nutrition food, functional indication food), food for special use (for example, food for infants, food for pregnant women, disease, etc.) Food).
- the form of “food” is not particularly limited, and may be, for example, a beverage form, a semi-liquid or gel form, or a solid form.
- cocoa polyphenol Since cocoa polyphenol has a BDNF production promoting action, it can be provided by being included in foods taken daily or foods taken as supplements.
- the food provided in the present invention is not particularly limited in its form or shape, but preferably includes foods mainly made from cocoa beans, more preferably an oil and fat processing composition, and even more preferably. Is chocolate and cocoa.
- a concentrated cocoa polyphenol composition can be used in the present invention in order to efficiently ingest cocoa polyphenol. Therefore, the food and supplement mainly made from cocoa beans are preferably those containing a high concentration of cocoa polyphenols, more preferably an oil and fat processing composition containing a high concentration of cocoa polyphenols, and even more preferably cocoa polyphenols. Chocolate and cocoa with a high concentration of polyphenols.
- the content of the cocoa polyphenol in the food and supplement is not particularly limited as long as the cocoa polyphenol can be ingested.
- the content in the fat and oil processing composition can be, for example, 1 to 10% by weight, preferably 1.2 to 8% by weight, more preferably 1.4 to 6% by weight, and still more preferably 1.6%, based on the solid content of the composition. Is 4 to 4% by mass, more preferably 1.8 to 3.5% by mass, and particularly preferably 2 to 3.4% by mass.
- the food provided in the present invention is not particularly limited as long as it is a food that can contain cocoa polyphenols as well as foods mainly made from cocoa beans such as chocolate and cocoa.
- cocoa polyphenols for example, starch-based foods such as breads, biscuits, noodles, crackers, nutrition bars; confectioneries such as candies, gums, gummi, snacks; milk, processed milk, ice cream, fermented milk (yogurt, etc.) ), Milk and dairy products such as milk drinks, cheeses, butters and creams; desserts such as pudding, jelly, bavaroa and mousse; beverages such as non-alcoholic drinks and alcoholic drinks; processing of meat such as ham and sausage Products; processed fish products such as sea cucumbers, bamboo rings and fish sausages; processed fruit products such as jams and purees; seasonings such as roux and sauces.
- Cocoa polyphenol can be appropriately blended at the stage of an appropriate production process according to the characteristics and purpose of each food.
- cocoa polyphenol contained in cacao beans that have long been used as foods, mammals (for example, humans, mice, rats, rabbits, dogs, cats, Cattle, horses, pigs, monkeys, etc.).
- the dose or intake of cocoa polyphenol can be determined depending on the recipient's sex, age and weight, symptoms, administration time, dosage form, administration route, combined drugs and the like.
- cocoa polyphenol is orally administered as a medicine, it is 10 to 2000 mg, preferably 50 to 1800 mg, more preferably 100 to 1600 mg, even more preferably 150 to 1500 mg, still more preferably 200 to 1400 mg, particularly preferably, per adult day.
- cocoa polyphenol is ingested as a food, it is 10 to 2000 mg, preferably 50 to 1800 mg, more preferably 100 to 1600 mg, still more preferably 150 to 1500 mg, still more preferably 200 to 1400 mg per day for an adult.
- the cocoa polyphenol can be ingested in a range of preferably 300 to 1200 mg, more preferably 400 to 1100 mg, and most preferably 500 to 1000 mg.
- the composition for promoting BDNF production and the BDNF production promoter of the present invention and the therapeutic agent, preventive agent and ameliorating agent of the present invention have a low initial value of serum BDNF protein concentration. And can be administered or ingested to non-human animals.
- the BDNF production promotion method of the present invention and the treatment method, prevention method and improvement method of the present invention are carried out on human and non-human animals having a low initial value of serum BDNF protein concentration.
- human and non-human animals having a low initial value of serum BDNF protein concentration means that the serum BDNF concentration before ingestion (day 0) is 0.1 to 6 ng / ml, preferably 0.1 to 5.5 ng.
- / Ml more preferably 0.1 to 5 ng / ml, even more preferably 0.1 to 4.5 ng / ml, still more preferably 0.1 to 4 ng / ml, particularly preferably 0.1 to 3 ng / ml, More preferably, it is 0.1 to 2.5 ng / ml, and most preferably 0.1 to 2 ng / ml.
- composition for promoting BDNF production and the BDNF production promoter of the present invention are not limited to use in combination with other compositions that can be taken orally.
- the effect of promoting BDNF production can be further enhanced.
- the composition for promoting BDNF production and the BDNF production promoter of the present invention can be provided as a composition comprising a daily intake of cacao polyphenol effective for promoting BDNF production.
- the composition for promoting BDNF production and the BDNF production promoter may be packaged so that the effective intake for one day can be ingested, and as long as the effective intake for one day can be ingested, the packaging form May be a single package or a plurality of packages.
- the packaging form May be a single package or a plurality of packages.
- a plurality of packages with the effective intake for one day can be provided as a set for convenience of intake.
- the packaging form for providing the composition for promoting BDNF production and the BDNF production promoting agent of the present invention is not particularly limited as long as it is a form that defines a certain amount.
- wrapping paper, bag, soft bag, paper container And can accommodate containers such as cans, bottles, capsules and the like.
- composition for promoting BDNF production and the BDNF production promoter of the present invention are preferably administered or ingested continuously for 2 weeks or more in order to better exert their effects, and the administration and ingestion period is more preferably 2 ⁇ 8 weeks, particularly preferably 4-8 weeks.
- “continuously” means to continue administration or ingestion every day.
- an effective intake for a certain period for example, one week is provided as a set for continuous intake. Also good.
- Example 1 Examination of BDNF production promotion effect by cocoa polyphenol The following test was conducted in order to verify the influence of cocoa polyphenol on BDNF production.
- cocoa polyphenol-rich oil and fat composition (“Chocolate effect cacao 72%” Meiji Co., Ltd.) Were taken continuously for 5 weeks. Since the said fats-and-oils processing composition contains 127 mg (total polyphenol amount) of cocoa polyphenols per sheet, the cocoa polyphenol that the subject ingests per day is 635 mg.
- the content of 1- to 4-mer polyphenols to be ingested in the above-mentioned oil and fat processing composition was 76 mg.
- the breakdown of the main components is 10.4 mg of catechin (monomer), 27.8 mg of epicatechin (monomer), 15.8 mg of procyanidin B2 (dimer), and procyanidin B5 (dimer).
- procyanidin C1 (trimer) was 9.6 mg
- cinnamtannin A2 (tetramer) was 7.1 mg.
- Develosil-ODS-HG5 (4.6 mm ⁇ 250 mm, ⁇ 5 ⁇ , manufactured by Nomura Chemical Co., Ltd.) was used as the column.
- the eluent was composed of liquid A and liquid B.
- the liquid A was a 0.1% trifluoroacetic acid aqueous solution
- the liquid B was a 0.1% trifluoroacetic acid / acetonitrile solution.
- the flow rate of the eluent passed through the column is 0.8 ml / min.
- the gradient conditions are as follows: the ratio of B solution in the total eluent is 10% at the start, 10% after 5 minutes, and 35 minutes after start. 25%, 100% after 40 minutes from the start, and 100% after 45 minutes from the start.
- the sample injection amount was 10 ⁇ L
- epicatechin was used as a standard product, and each component was quantified by epicatechin equivalent.
- the polyphenol content was measured by the Prussian blue method. Specifically, according to the method described in Martin L. Price and Larry G. Butler, J. Agric Food Chem., Vol. 25, No.6, 1268-1273, 1977, using commercially available epicatechin as a standard substance,
- BDNF protein concentration in the serum was measured.
- BDNF is related to mood control, and serum BDNF concentration decreases in depressed patients, but it has been reported that BDNF concentration in serum recovers when an antidepressant is successful (Non-patent Document 1). Therefore, a subject whose serum BDNF concentration before intake (day 0) is the first quartile or lower (the serum BDNF concentration is 4.38 ng / ml or lower) is defined as a subject with a low initial value, and the same as above. We performed Wilcoxon's sign rank test.
- cocoa polyphenol promotes BDNF production
- ingestion of cocoa polyphenol has an effect of improving diseases and medical conditions that are improved by promoting BDNF production such as depression.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Abstract
Description
[1]カカオポリフェノールを含んでなる、脳由来神経因子(BDNF)の産生促進のための組成物およびBDNF産生促進剤。
[2]カカオポリフェノールが1~4量体のポリフェノール類を8質量%以上含んでなるものである、前記[1]に記載のBDNF産生促進用組成物およびBDNF産生促進剤。
[3]BDNF産生促進に有効な1日分の摂取量のカカオポリフェノールを含んでなる、前記[1]または[2]に記載のBDNF産生促進用組成物およびBDNF産生促進剤。
[4]1日分の有効摂取量ごとに包装されてなる、前記[3]に記載のBDNF産生促進用組成物およびBDNF産生促進剤。
[5]BDNF産生促進に有効な1日分の摂取量が10~2000mg(ポリフェノール総量)である、前記[3]または[4]に記載のBDNF産生促進用組成物およびBDNF産生促進剤。
[6]カカオポリフェノールを2週間以上摂取させることを特徴とする、前記[1]~[5]のいずれかに記載のBDNF産生促進用組成物およびBDNF産生促進剤。
[6-1]カカオポリフェノールを、1日当たり10~2000mg(ポリフェノール総量)で2週間以上摂取させることを特徴とする、前記[1]~[6]のいずれかに記載のBDNF産生促進用組成物およびBDNF産生促進剤。
[7]油脂加工組成物の形態である、前記[1]~[6]および[6-1]のいずれかに記載のBDNF産生促進用組成物およびBDNF産生促進剤。
[8]カカオポリフェノールをBDNF産生促進に有効な1日分の摂取量で2週間以上摂取させることを含んでなる、BDNFの産生促進方法。
[9]BDNF産生促進に有効な1日分の摂取量が10~2000mg(ポリフェノール総量)である、前記[8]に記載のBDNFの産生促進方法。
[10]カカオポリフェノールを油脂加工組成物の形態で摂取させることを特徴とする、前記[8]または[9]に記載のBDNFの産生促進方法。
[11]BDNFの産生促進のための組成物またはBDNF産生促進剤を製造するための、カカオポリフェノールの使用。
[12]カカオポリフェノールを含んでなる、BDNF産生促進がその治療、予防または改善に有効である疾患および症状の治療、予防または改善のための組成物、または該疾患および症状の治療、予防または改善剤。
[13]有効量のカカオポリフェノールを対象に投与することを含んでなる、BDNF産生促進がその治療、予防または改善に有効である疾患および症状の治療、予防または改善方法。
[14]BDNF産生促進がその治療、予防または改善に有効である疾患および症状の治療、予防または改善のための組成物、または該疾患および症状の治療、予防または改善剤を製造するための、カカオポリフェノールの使用。
カカオポリフェノールがBDNF産生に与える影響を検証するために以下の試験を行った。
Claims (11)
- カカオポリフェノールを含んでなる、脳由来神経因子(BDNF)の産生促進のための組成物。
- カカオポリフェノールが1~4量体のポリフェノール類を8質量%以上含んでなるものである、請求項1に記載の組成物。
- BDNF産生促進に有効な1日分の摂取量のカカオポリフェノールを含んでなる、請求項1または2に記載の組成物。
- 1日分の有効摂取量ごとに包装されてなる、請求項3に記載の組成物。
- BDNF産生促進に有効な1日分の摂取量が10~2000mg(ポリフェノール総量)である、請求項3または4に記載の組成物。
- カカオポリフェノールを2週間以上摂取させることを特徴とする、請求項1~5のいずれか一項に記載の組成物。
- 油脂加工組成物の形態である、請求項1~6のいずれか一項に記載の組成物。
- カカオポリフェノールをBDNF産生促進に有効な1日分の摂取量で2週間以上摂取させることを含んでなる、BDNFの産生促進方法(ただし、ヒトに対する医療行為を除く)。
- BDNF産生促進に有効な1日分の摂取量が10~2000mg(ポリフェノール総量)である、請求項8に記載のBDNFの産生促進方法。
- カカオポリフェノールを油脂加工組成物の形態で摂取させることを特徴とする、請求項8または9に記載のBDNFの産生促進方法。
- BDNFの産生促進のための組成物またはBDNF産生促進剤を製造するための、カカオポリフェノールの使用。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2983091A CA2983091A1 (en) | 2015-05-11 | 2016-05-10 | Composition for facilitating production of brain-derived neurotrophic factor |
SG11201708128XA SG11201708128XA (en) | 2015-05-11 | 2016-05-10 | Composition for promoting production of brain-derived neurotrophic factor |
JP2017517939A JP6894838B2 (ja) | 2015-05-11 | 2016-05-10 | 脳由来神経栄養因子の産生促進用組成物 |
CN201680027049.3A CN107530385A (zh) | 2015-05-11 | 2016-05-10 | 用于促进脑源性神经营养因子产生的组合物 |
US15/572,189 US10695317B2 (en) | 2015-05-11 | 2016-05-10 | Composition for promoting production of brain-derived neurotrophic factor |
EP16792670.8A EP3272351A4 (en) | 2015-05-11 | 2016-05-10 | Composition for facilitating production of brain-derived neurotrophic factor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015096205 | 2015-05-11 | ||
JP2015-096205 | 2015-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016181945A1 true WO2016181945A1 (ja) | 2016-11-17 |
Family
ID=57248002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/063797 WO2016181945A1 (ja) | 2015-05-11 | 2016-05-10 | 脳由来神経栄養因子の産生促進用組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10695317B2 (ja) |
EP (1) | EP3272351A4 (ja) |
JP (1) | JP6894838B2 (ja) |
CN (1) | CN107530385A (ja) |
CA (1) | CA2983091A1 (ja) |
SG (1) | SG11201708128XA (ja) |
WO (1) | WO2016181945A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018087171A (ja) * | 2016-11-29 | 2018-06-07 | 株式会社明治 | 交感神経活性化用組成物 |
WO2021172304A1 (ja) * | 2020-02-26 | 2021-09-02 | 株式会社マザー&チャイルド | エストロジェン分泌増進用組成物 |
WO2023210679A1 (ja) * | 2022-04-28 | 2023-11-02 | 国立大学法人九州大学 | 脳機能改善用組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530246A (ja) * | 2007-06-21 | 2010-09-09 | マース インコーポレーテッド | 高カカオポリフェノール含有量および改善された風味を有する食用製品並びにその中に使用される粉砕カカオ抽出物 |
WO2014144972A1 (en) * | 2013-03-15 | 2014-09-18 | Vdf Futureceuticals, Inc. | Compositions and methods of bdnf activation |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002250117B2 (en) | 2001-03-15 | 2007-11-29 | Cognitive Clarity Inc. | Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases |
WO2010073404A1 (ja) | 2008-12-26 | 2010-07-01 | 株式会社ニチレイバイオサイエンス | カシューアップルのプロアントシアニジン、プロアントシアニジン含有組成物、およびその用途 |
BRPI1008427A2 (pt) | 2009-02-13 | 2016-03-01 | Nestec Sa | produtos compreendendo amidas de aminoácidos n-fenilpropenoíla e uso das mesmas |
-
2016
- 2016-05-10 JP JP2017517939A patent/JP6894838B2/ja active Active
- 2016-05-10 WO PCT/JP2016/063797 patent/WO2016181945A1/ja active Application Filing
- 2016-05-10 CN CN201680027049.3A patent/CN107530385A/zh active Pending
- 2016-05-10 SG SG11201708128XA patent/SG11201708128XA/en unknown
- 2016-05-10 CA CA2983091A patent/CA2983091A1/en not_active Abandoned
- 2016-05-10 US US15/572,189 patent/US10695317B2/en active Active
- 2016-05-10 EP EP16792670.8A patent/EP3272351A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010530246A (ja) * | 2007-06-21 | 2010-09-09 | マース インコーポレーテッド | 高カカオポリフェノール含有量および改善された風味を有する食用製品並びにその中に使用される粉砕カカオ抽出物 |
WO2014144972A1 (en) * | 2013-03-15 | 2014-09-18 | Vdf Futureceuticals, Inc. | Compositions and methods of bdnf activation |
Non-Patent Citations (9)
Title |
---|
BISSON, J.F. ET AL.: "Effects of long-term administration of a cocoa polyphenolic extract (Acticoa powder) on cognitive performances in aged rats", BR. J. NUTR., vol. 100, no. 1, July 2008 (2008-07-01), pages 94 - 101, XP055151978, ISSN: 0007-1145 * |
CIMINI, A. ET AL.: "Cocoa Powder Triggers Neuroprotective and Preventive Effects in a Human Alzheimer's Disease Model by Modulating BDNF Signaling Pathway", J. CELL . BIOCHEM., vol. 114, no. 10, 13 October 2013 (2013-10-13), pages 2209 - 2220, XP055329326, ISSN: 1097-4644 * |
HOU, Y. ET AL.: "Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice", NEUROPHARMACOL., vol. 58, no. 6, 13 May 2010 (2010-05-13), pages 911 - 920, XP026954346, ISSN: 0028-3908 * |
KATSUMASA SHIMIZU ET AL.: "Deodorizing Effect of Cacao Polyphenols against Methyl Mercaptan", JOURNAL OF THE JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY, vol. 48, no. 4, 15 April 2001 (2001-04-15), pages 238 - 245, XP055329318, ISSN: 1341-027X * |
MIDORI NATSUME: "Tokushu Gan Yobo to Kinosei Shokuhin 10. Cacao Polyphenol no Hatsugan Yokusei Sayo", FUNCT. FOOD, vol. 4, no. 4, 30 April 2011 (2011-04-30), pages 374 - 378, XP009507051, ISSN: 1882-3971 * |
See also references of EP3272351A4 * |
STRINGER, T.P. ET AL.: "Plant-derived flavonol (-)epicatechin mitigates anxiety in association with elevated hippocampal monoamine and BDNF levels, but does not influence pattern separation in mice", TRANSL. PSYCHIATRY, vol. 5, no. 1, 2014, pages 1 - 9, XP055329316, ISSN: 2158-3188 * |
TIAN, W. ET AL.: "Intrathecal Epigallocatechin Gallate Treatment Improves Functional Recovery After Spinal Cord Injury by Upregulating the Expression of BDNF and GDNF", NEUROCHEM. RES., vol. 38, no. 4, April 2013 (2013-04-01), pages 772 - 779, XP055329329, ISSN: 0364-3190 * |
YUKO KITAURA ET AL.: "31-0681 Ashitaba Yurai Chalcone-rui ni yoru Neurotrophin Sansei Sokushin Sayo", ABSTRACTS OF ANNUAL MEETING OF PHARMACEUTICAL SOCIETY OF JAPAN, vol. 125, no. 4, 5 March 2005 (2005-03-05), pages 132, XP009507056, ISSN: 0918-9823 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018087171A (ja) * | 2016-11-29 | 2018-06-07 | 株式会社明治 | 交感神経活性化用組成物 |
US11147791B2 (en) | 2016-11-29 | 2021-10-19 | Meiji Co., Ltd. | Composition for activating sympathetic nerve |
WO2021172304A1 (ja) * | 2020-02-26 | 2021-09-02 | 株式会社マザー&チャイルド | エストロジェン分泌増進用組成物 |
WO2023210679A1 (ja) * | 2022-04-28 | 2023-11-02 | 国立大学法人九州大学 | 脳機能改善用組成物 |
Also Published As
Publication number | Publication date |
---|---|
US10695317B2 (en) | 2020-06-30 |
US20180117001A1 (en) | 2018-05-03 |
JPWO2016181945A1 (ja) | 2018-03-01 |
CN107530385A (zh) | 2018-01-02 |
SG11201708128XA (en) | 2017-11-29 |
EP3272351A1 (en) | 2018-01-24 |
CA2983091A1 (en) | 2016-11-17 |
EP3272351A4 (en) | 2018-12-05 |
JP6894838B2 (ja) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101473017B1 (ko) | 노화 억제제 | |
CN101484158B (zh) | 衰老抑制剂 | |
JP6208604B2 (ja) | 体脂肪低減剤 | |
US8420116B2 (en) | Dietary compositions for promoting weight loss | |
JP6894838B2 (ja) | 脳由来神経栄養因子の産生促進用組成物 | |
JP4839436B2 (ja) | 消化管粘膜保護剤、カベオリン遺伝子発現促進剤及び抗ストレス剤 | |
WO2006135084A1 (ja) | 脂肪性肝炎または脂肪肝の予防または治療薬 | |
JP2008063318A (ja) | 老化抑制剤 | |
TWI784004B (zh) | 乙酸及/或乙酸鹽用以製造腦功能改善用組成物之用途 | |
WO2017026471A1 (ja) | 動脈スティフネス改善用組成物 | |
WO2011145909A2 (ko) | 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물의 근육 증가 촉진, 항-피로 및 운동수행능력 향상에 관한 새로운 용도 | |
US11147791B2 (en) | Composition for activating sympathetic nerve | |
JP2018095580A (ja) | 抗不安用組成物 | |
JP7225503B2 (ja) | 新規なカカオポリフェノール含有血圧上昇抑制用組成物 | |
WO2015190682A1 (ko) | 쿠마린산을 유효성분으로 포함하는 성장 촉진용 조성물 | |
JP2008169143A (ja) | テアニン含有神経細胞新生促進組成物及び飲食物 | |
TW201424743A (zh) | Igf-1產生促進劑 | |
JP2019180399A (ja) | 食後の血糖値上昇抑制用組成物 | |
WO2024071138A1 (ja) | ミトコンドリア機能向上用組成物 | |
JPWO2019054461A1 (ja) | 神経機能の維持または回復用組成物 | |
KR101970353B1 (ko) | 몰루긴 및 bmp-2를 포함하는 골 질환의 예방 또는 치료용 조성물 | |
JP2022104122A (ja) | オキシトシン関連シグナル活性化剤 | |
WO2006135083A1 (ja) | 内臓脂肪症候群の予防または治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16792670 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201708128X Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 2017517939 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2983091 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15572189 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |